Important Safety Information

Emergency symptoms

Call 911 or seek immediate emergency care for trouble breathing, swelling of the face or throat, severe allergic reaction, chest pain, fainting, signs of stroke, severe or persistent abdominal pain, uncontrolled vomiting with inability to keep fluids down, confusion, suicidal thoughts, or any symptom you believe may be life-threatening. This service does not provide emergency care.

Compounded medications

Compounded medications are not FDA approved. FDA does not review them for safety, effectiveness, or quality before marketing. Potency, inactive ingredients, formulation, packaging, appearance, storage, and absorption may differ from FDA-approved products. Use only the medication dispensed for you and follow the provider's and pharmacy's instructions.

Semaglutide and tirzepatide

GLP-1 medications, including semaglutide, and dual GIP/GLP-1 medications, including tirzepatide, may cause nausea, vomiting, diarrhea, constipation, abdominal discomfort, decreased appetite, indigestion, fatigue, injection-site reactions, and other effects. Serious risks may include pancreatitis, gallbladder problems, dehydration and kidney injury, severe gastrointestinal problems, allergic reactions, hypoglycemia when used with certain diabetes medications, and possible worsening of diabetic retinopathy with rapid glucose improvement.

Do not use a semaglutide- or tirzepatide-containing treatment if you or a family member has had medullary thyroid carcinoma or if you have Multiple Endocrine Neoplasia syndrome type 2. Tell your provider about pregnancy, plans for pregnancy, breastfeeding, diabetes, kidney disease, pancreas or gallbladder problems, severe digestive disease, diabetic eye disease, surgery, eating disorders, and all medications and supplements. Do not combine products containing the same or similar GLP-1 ingredients unless specifically directed by a provider.

Compounded oral tirzepatide

There is no FDA-approved oral tirzepatide product. Its absorption, bioavailability, effectiveness, and risk profile have not been established as equivalent to FDA-approved injectable tirzepatide. Follow the exact administration instructions provided by the prescriber and pharmacy and report unexpected symptoms or lack of effect.

GLP-1 low-dose or microdosing programs

“Microdosing” describes a lower-dose prescribing approach, not a separately FDA-approved medication. The same active-ingredient contraindications, interaction concerns, pregnancy considerations, and potentially serious adverse effects may still apply even at a lower dose. Lower dosing does not guarantee fewer side effects or a particular outcome.

NAD+ injection or nasal spray

Compounded NAD+ preparations are not FDA approved for improving energy, longevity, recovery, cognition, or performance. Report significant flushing, chest tightness, shortness of breath, severe nausea, dizziness, headache, injection-site reactions, nasal irritation, allergic symptoms, or other concerning effects. Sterility and administration technique are especially important for injectable products.

Sermorelin

Sermorelin treatment may cause injection-site reactions, flushing, headache, dizziness, sleep changes, nausea, swelling, tingling, or allergic reactions and may affect growth-hormone and glucose-related laboratory values. Tell your provider about pregnancy or breastfeeding, cancer or tumor history, pituitary or endocrine disorders, diabetes, sleep apnea, swelling, and all medications. The compounded use offered through the service is not FDA approved for anti-aging, body-composition, recovery, or performance outcomes.

MIC with vitamin B12

MIC and vitamin B12 injections may cause pain, redness, swelling, nausea, diarrhea, headache, dizziness, itching, or allergic reactions. Evidence does not establish that a compounded MIC+B12 injection produces guaranteed weight loss, fat burning, metabolic improvement, or increased energy. Tell your provider about allergies, kidney or liver disease, pregnancy, breastfeeding, and all medications and supplements.

GHK-Cu cream and oral preparations

Compounded GHK-Cu preparations are not FDA approved to treat disease or guarantee anti-aging, collagen, hair-growth, healing, or skin-regeneration outcomes. Topical products may cause redness, itching, burning, irritation, rash, or allergy. Avoid eyes, mucous membranes, and broken skin unless directed. Safety and effectiveness information for oral compounded GHK-Cu is limited; use only under provider direction and report concerning reactions.

Pregnancy, breastfeeding, and contraception

Many treatments offered through the service may be inappropriate during pregnancy, while trying to become pregnant, or while breastfeeding. Tell your provider immediately if you are pregnant, may be pregnant, plan pregnancy, or are breastfeeding. Some medications require discontinuation before planned pregnancy. Tirzepatide may affect absorption of oral contraceptives during dose initiation and escalation; ask your provider about backup contraception.

Drug interactions and procedures

Give your provider and pharmacist a complete list of prescription drugs, over-the-counter medicines, vitamins, supplements, and other compounded products. Tell every clinician caring for you about these treatments, especially before surgery, anesthesia, sedation, or a procedure, because slowed stomach emptying and other medication effects may change procedural risk.

Storage, dosing, and sharing

Follow the dispensing label for dose, route, timing, refrigeration, protection from light, beyond-use date, and disposal. Do not change the dose, use more frequently, transfer medication to another container, or use a product that appears damaged or improperly stored without speaking to the pharmacy or provider. Never share prescription medication or injection supplies.

Ongoing monitoring

Complete requested follow-up, laboratory testing, symptom reporting, and vital-sign or weight monitoring. Contact the provider if side effects persist, health conditions change, you start another medication, treatment is ineffective, or you want to stop. The provider may adjust, pause, or discontinue treatment for safety.

Pharmacy and adverse-event contact

Questions about the dispensed product, storage, labeling, shipping temperature, or suspected quality problems should be directed to the dispensing pharmacy listed on your prescription label. Side effects should be reported to your provider. Serious adverse events or quality concerns may also be reported to FDA MedWatch at fda.gov/medwatch.